Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (145)	7/13/1999 10:01:00 AM
From: BridgeTech	Respond to of 370

SmallCaps Online LLC Initiates Coverage of Vion Pharmaceuticals, Inc. with a BUY Recommendation Release: biz.yahoo.com Report: smallcapsonline.com

To: Jim Oravetz who wrote (145)	7/16/1999 8:49:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Contemplates Public Offering of Common Stock NEW HAVEN, Conn., July 15 /PRNewswire/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION - news) today announced it intends to file a registration statement with the Securities and Exchange Commission relating to the offering of shares of its common stock to the public in a secondary offering. The exact size and timing of the offering has not yet been determined. If consummated, this offering will be made only by means of a prospectus. Vion Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing novel products and technologies for the treatment of cancer. The Company has focused its research efforts on five principal areas: hypoxic cancer cell therapeutics, TAPET cancer therapy, sulfonyl hydrazine prodrugs, ribonucleotide reductase inhibitors and nucleoside analogs. For additional information on Vion and its research and product development programs, visit the Company's Internet web site at vionpharm.com.